Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Herbalife Nutrition Ltd (HLF) vs Medtronic PLC (MDT) Price & Performance

Herbalife Nutrition LtdTrade
Medtronic PLCTrade

Price performance (Past 24H)

Key statistics

Herbalife Nutrition Ltd vs Medtronic PLC — how do they compare? Herbalife Nutrition Ltd trades at $11.76 (market cap $1.23B), while Medtronic PLC trades at $90.61 (market cap $116.07B). The key difference: Medtronic PLC is far larger — about 94.4× Herbalife Nutrition Ltd's market cap, and Medtronic PLC pays a 3.18% dividend while Herbalife Nutrition Ltd pays none. Which is the better fit depends on your goals.

HLFMDT
Market Cap
$1.23B$116.07B
Sector
Consumer StaplesHealth
52-Week High
$19.96$105.35
52-Week Low
$7.75$73.75
Enterprise Value
$3.06B$134.82B
Dividend Yield
3.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Herbalife Nutrition Ltd

Herbalife (HLF) trades at $11.695, up 1.52% on the day, with a bearish technical outlook per moving averages. The company reported Q2 2026 net sales of $1.3 billion, a 5.4% year-over-year increase, though EPS of $0.51 missed estimates. Valuation ratios appear attractive with a P/E of 7.53 and P/S of 0.24. Positive news includes being named to TIME's America's Best Companies 2026 list, but a planned CFO transition in December 2026 introduces uncertainty.

The outlook is mixed; strong sales growth and low valuation metrics offer potential upside, but recent earnings misses, a high debt load, and negative shareholder equity pose significant risks. Analyst consensus leans bullish with 53.84% buy ratings, yet the stock faces headwinds from competitive pressures and margin volatility.

Medtronic PLC

Medtronic (MDT) trades at $90.70, up 1.44% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.55 beating expectations of $1.54. Revenue growth accelerated to $33.54 billion in 2025 with improving profit margins of 13.2%. Recent positive developments include new product approvals and institutional accumulation, though RSI levels suggest potential near-term overbought conditions.

The outlook remains positive with analyst consensus targeting $98.75 (8.9% upside) and no sell ratings. Key opportunities include robotic surgery platform expansion and cardiac ablation growth, while risks involve rising debt levels and competitive pressures. The stock offers dividend stability with a $0.72 upcoming payment, making it attractive for income-focused investors seeking medical technology exposure.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Herbalife Nutrition Ltd

Herbalife Nutrition Ltd is an international nutrition company.

Read more on HLF

About Medtronic PLC

One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.

Read more on MDT